Cargando…

In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model

Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission...

Descripción completa

Detalles Bibliográficos
Autores principales: Csikos, Csaba, Vágner, Adrienn, Nagy, Gábor, Kálmán-Szabó, Ibolya, Szabó, Judit P., Ngo, Minh Toan, Szoboszlai, Zoltán, Szikra, Dezső, Krasznai, Zoárd Tibor, Trencsényi, György, Garai, Ildikó
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858384/
https://www.ncbi.nlm.nih.gov/pubmed/36673046
http://dx.doi.org/10.3390/diagnostics13020236
_version_ 1784874085603344384
author Csikos, Csaba
Vágner, Adrienn
Nagy, Gábor
Kálmán-Szabó, Ibolya
Szabó, Judit P.
Ngo, Minh Toan
Szoboszlai, Zoltán
Szikra, Dezső
Krasznai, Zoárd Tibor
Trencsényi, György
Garai, Ildikó
author_facet Csikos, Csaba
Vágner, Adrienn
Nagy, Gábor
Kálmán-Szabó, Ibolya
Szabó, Judit P.
Ngo, Minh Toan
Szoboszlai, Zoltán
Szikra, Dezső
Krasznai, Zoárd Tibor
Trencsényi, György
Garai, Ildikó
author_sort Csikos, Csaba
collection PubMed
description Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission tomography using radiolabeled target-specific antibodies (immuno-PET) provides the longitudinal and quantitative assessment of tumor target expression. Due to antibodies having a long-circulating time, radioactive metal ions (e.g., (52)Mn) with longer half-lives are the best candidates for isotope conjugation. The aim of our preclinical study was to assess the biodistribution and tumor-targeting potential of (52)Mn-labeled DOTAGA-bevacizumab. The VEGF-A targeting potential of the new immuno-PET ligand was assessed by using the VEGF-A expressing KB-3-1 (human cervix carcinoma) tumor-bearing CB17 SCID mouse model and in vivo PET/MRI imaging. Due to the high and specific accumulation found in the subcutaneously located experimental cervix carcinoma tumors, [(52)Mn]Mn-DOTAGA-bevacizumab is a promising PET probe for the detection of VEGF-A positive gynecological tumors, for patient selection, and monitoring the efficacy of therapies targeting angiogenesis.
format Online
Article
Text
id pubmed-9858384
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98583842023-01-21 In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model Csikos, Csaba Vágner, Adrienn Nagy, Gábor Kálmán-Szabó, Ibolya Szabó, Judit P. Ngo, Minh Toan Szoboszlai, Zoltán Szikra, Dezső Krasznai, Zoárd Tibor Trencsényi, György Garai, Ildikó Diagnostics (Basel) Article Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission tomography using radiolabeled target-specific antibodies (immuno-PET) provides the longitudinal and quantitative assessment of tumor target expression. Due to antibodies having a long-circulating time, radioactive metal ions (e.g., (52)Mn) with longer half-lives are the best candidates for isotope conjugation. The aim of our preclinical study was to assess the biodistribution and tumor-targeting potential of (52)Mn-labeled DOTAGA-bevacizumab. The VEGF-A targeting potential of the new immuno-PET ligand was assessed by using the VEGF-A expressing KB-3-1 (human cervix carcinoma) tumor-bearing CB17 SCID mouse model and in vivo PET/MRI imaging. Due to the high and specific accumulation found in the subcutaneously located experimental cervix carcinoma tumors, [(52)Mn]Mn-DOTAGA-bevacizumab is a promising PET probe for the detection of VEGF-A positive gynecological tumors, for patient selection, and monitoring the efficacy of therapies targeting angiogenesis. MDPI 2023-01-08 /pmc/articles/PMC9858384/ /pubmed/36673046 http://dx.doi.org/10.3390/diagnostics13020236 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Csikos, Csaba
Vágner, Adrienn
Nagy, Gábor
Kálmán-Szabó, Ibolya
Szabó, Judit P.
Ngo, Minh Toan
Szoboszlai, Zoltán
Szikra, Dezső
Krasznai, Zoárd Tibor
Trencsényi, György
Garai, Ildikó
In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
title In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
title_full In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
title_fullStr In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
title_full_unstemmed In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
title_short In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
title_sort in vivo preclinical assessment of the vegf targeting potential of the newly synthesized [(52)mn]mn-dotaga-bevacizumab using experimental cervix carcinoma mouse model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858384/
https://www.ncbi.nlm.nih.gov/pubmed/36673046
http://dx.doi.org/10.3390/diagnostics13020236
work_keys_str_mv AT csikoscsaba invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT vagneradrienn invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT nagygabor invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT kalmanszaboibolya invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT szabojuditp invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT ngominhtoan invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT szoboszlaizoltan invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT szikradezso invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT krasznaizoardtibor invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT trencsenyigyorgy invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel
AT garaiildiko invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel